KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis

2017, Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 390, 1151, 10.1016/S0140-6736(17)32152-9 Goldberg, 2013, A step towards treating KRAS-mutant NSCLC, Lancet Oncol., 14, 3, 10.1016/S1470-2045(12)70528-4 Brose, 2002, BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res., 62, 6997 Okudela, 2010, KRAS gene mutations in lung cancer: particulars established and issues unresolved, Pathol. Int., 60, 651, 10.1111/j.1440-1827.2010.02580.x Rodenhuis, 1987, Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung, N. Engl. J. Med., 317, 929, 10.1056/NEJM198710083171504 Kosaka, 2004, Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications, Cancer Res., 64, 8919, 10.1158/0008-5472.CAN-04-2818 Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 19, 4273, 10.1158/1078-0432.CCR-13-0318 Roberts, 2010, Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy, J. Clin. Oncol., 28, 4769, 10.1200/JCO.2009.27.4365 Zer, 2016, Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors, J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer, 11, 312, 10.1016/j.jtho.2015.11.010 Goldman, 2016, Clin. Lung Cancer, 17, 80, 10.1016/j.cllc.2015.08.003 Wood, 2016, Prognostic and predictive value in kras in non–small-cell lung cancer: a review, JAMA Oncol., 2, 805, 10.1001/jamaoncol.2016.0405 Meng D., Yuan M., Li X., et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer.81(1):1–10. Mascaux, 2005, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis, Br. J. Cancer, 92, 131, 10.1038/sj.bjc.6602258 Sun, 2013, Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer, PLoS ONE, 8, e64816, 10.1371/journal.pone.0064816 Ciuleanu, 2012, Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study, Lancet Oncol., 13, 300, 10.1016/S1470-2045(11)70385-0 Yu, 2015, Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, 10, 431, 10.1097/JTO.0000000000000432 Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J. Natl. Cancer Inst., 104, 228, 10.1093/jnci/djr523 Linardou, 2008, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, Lancet Oncol., 9, 962, 10.1016/S1470-2045(08)70206-7 Mao, 2010, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies, Lung Cancer, 69, 272, 10.1016/j.lungcan.2009.11.020 Riley, 2013, Prognosis Research Strategy (PROGRESS) 2: prognostic Factor Research, PLoS Med., 10, 10.1371/journal.pmed.1001380 Bormann I. DigitizeIt. 2012. Guyot, 2012, Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves, BMC Med. Res. Methodol., 12, 9, 10.1186/1471-2288-12-9 Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ (Clin. Res. Ed.), 343, d5928, 10.1136/bmj.d5928 Wells GSOC, D.; Peterson, J.; Welch, V.; Losos, M.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2103; http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed October 1, 2016. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat. Med., 21, 1539, 10.1002/sim.1186 Egger M, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ (Clin. Res. Ed.), 315, 629, 10.1136/bmj.315.7109.629 Spiegelhalter D., Thomas A., Best N., Lunn D. WinBUGS user manual version 1.4. 2003. Lunn D., Spiegelhalter D Fau - Thomas A, Thomas A Fau - Best N, Best N. The BUGS project: evolution, critique and future directions. (1097-0258 (Electronic)). Clark, 2008, Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib, Mol. Oncol., 1, 406, 10.1016/j.molonc.2007.12.001 Ramalingam SSJ, 2014, Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial, The Lancet, 15, 1369, 10.1016/S1470-2045(14)70452-8 Kabbinavar, 2014, Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS), J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer, 9, 1411, 10.1097/JTO.0000000000000274 Yoshioka, 2015, Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol., 26, 2066, 10.1093/annonc/mdv288 Blumenschein, 2013, Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial, Clin. Cancer Res., 19, 6967, 10.1158/1078-0432.CCR-12-1818 Kim, 2011, The BATTLE Trial: personalizing Therapy for Lung Cancer, Cancer Discov., 1, 44, 10.1158/2159-8274.CD-10-0010 Papadimitrakopoulou, 2016, The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer, J. Clin. Oncol., 34, 3638, 10.1200/JCO.2015.66.0084 Herbst, 2011, Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial, Lancet, 377, 1846, 10.1016/S0140-6736(11)60545-X Khambata-Ford, 2010, Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 28, 918, 10.1200/JCO.2009.25.2890 Zhu, 2008, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21, J. Clin. Oncol., 26, 4268, 10.1200/JCO.2007.14.8924 Ellis, 2014, Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial, The Lancet, 15, 1379, 10.1016/S1470-2045(14)70472-3 Camidge, 2011, Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed, J. Thorac. Oncol., 6, 774, 10.1097/JTO.0b013e31820cf053 Campos-Parra, 2015, KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making, Am. J. Clin. Oncol.: Cancer Clin. Trials, 38, 33, 10.1097/COC.0b013e318287bb23 Carter, 2016, Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer, Ann. Oncol., 27, 693, 10.1093/annonc/mdw008 Borghaei, 2015, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Cserepes, 2014, Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy, Eur. J. Cancer, 50, 1819, 10.1016/j.ejca.2014.04.001 Drilon, 2016, Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers, Ann. Oncol., 27, 1286, 10.1093/annonc/mdw163 Mok, 2016, Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer, Lung Cancer, 98, 1, 10.1016/j.lungcan.2016.04.023 O'Byrne, 2011, Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study, Lancet Oncol., 12, 795, 10.1016/S1470-2045(11)70189-9 Groen, 2013, A randomized, double-blind, phase ii study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC), Ann. Oncol., 24, 2382, 10.1093/annonc/mdt212 Hames, 2016, Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer, Lung Cancer, 92, 29, 10.1016/j.lungcan.2015.11.004 Hirsch, 2011, J. Clin. Oncol., 29, 3567, 10.1200/JCO.2010.34.4929 Karampeazis, 2013, Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study, Cancer, 119, 2754, 10.1002/cncr.28132 Douillard, 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 28, 744, 10.1200/JCO.2009.24.3030 Hirsch FRV-G, 2006, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 24, 5034, 10.1200/JCO.2006.06.3958 Jackman, 2009, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials, Clin. Cancer Res., 15, 5267, 10.1158/1078-0432.CCR-09-0888 Johnson, 2013, Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas, Cancer, 119, 356, 10.1002/cncr.27730 Okamoto, 2014, Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study, Oncotarget, 5, 2293, 10.18632/oncotarget.1906 Lynch, 2009, A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer, J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer, 4, 1002, 10.1097/JTO.0b013e3181aba89f Macerelli, 2014, Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?, Lung Cancer, 83, 383, 10.1016/j.lungcan.2013.12.013 Scagliotti GvP, 2015, Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 33, 2667, 10.1200/JCO.2014.60.7317 Milella, 2012, EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy, J. Thoracic Oncol., 7, 672, 10.1097/JTO.0b013e31824a8bde Paz-Ares, 2015, J. Thoracic Oncol., 10, 1745, 10.1097/JTO.0000000000000693 Spigel, 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 31, 4105, 10.1200/JCO.2012.47.4189 Ramalingam, 2012, Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 30, 3337, 10.1200/JCO.2011.40.9433 Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.[Erratum appears in J Clin Oncol. 2011 Dec 10;29(35):4725], J. Clin. Oncol., 29, 4113, 10.1200/JCO.2010.31.8162 Sequist, 2011, Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 29, 3307, 10.1200/JCO.2010.34.0570 Spigel, 2011, Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 29, 2582, 10.1200/JCO.2010.30.7678 Hirsch, 2007, Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib, Ann. Oncol., 18, 752, 10.1093/annonc/mdm003 Garassino, 2013, Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial, Lancet Oncol., 14, 981, 10.1016/S1470-2045(13)70310-3 Rulli, 2015, Tailor trialists. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial, Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol., 26, 2079, 10.1093/annonc/mdv318 Lee, 2012, First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial, The Lancet, 13, 1161, 10.1016/S1470-2045(12)70412-6 Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 23, 5900, 10.1200/JCO.2005.02.857 Heymach, 2014, EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer, Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol., 25, 1941, 10.1093/annonc/mdu269 CQdCS, 2008, National Cancer Institute of Canada Clinical Trials Group Study, B. R. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21, J. Clin. Oncol., 26, 4268, 10.1200/JCO.2007.14.8924